LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
141.56
+0.65 (+0.46%)
At close: 4:04PM EST
Stock chart is not supported by your current browser
Previous Close140.91
Open141.25
Bid140.90 x 800
Ask141.61 x 1100
Day's Range140.69 - 142.25
52 Week Range101.36 - 142.25
Volume2,482,734
Avg. Volume3,514,879
Market Cap135.916B
Beta (5Y Monthly)0.20
PE Ratio (TTM)17.15
EPS (TTM)8.26
Earnings DateJan 29, 2020
Forward Dividend & Yield2.96 (2.10%)
Ex-Dividend DateFeb 11, 2020
1y Target Est133.08
  • Health stocks reverse coronavirus gains as one analyst says the market is overreacting
    Yahoo Finance

    Health stocks reverse coronavirus gains as one analyst says the market is overreacting

    Virus originating in Wuhan, China affected stock markets Tuesday, but one analyst said reactions were too strong.

  • Steven Cohen's Point72 Piles Into Menlo Therapeutics
    GuruFocus.com

    Steven Cohen's Point72 Piles Into Menlo Therapeutics

    Billionaire investor’s firm makes real-time trade in biotech company that focuses on pruritus treatments Continue reading...

  • Durham is on a winning streak for new jobs, but will it continue?
    American City Business Journals

    Durham is on a winning streak for new jobs, but will it continue?

    Durham has the talent, and the momentum, when it comes to winning big job expansions. Here's what an eco devo exec says needs to happen to maintain its winning ways.

  • Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
    Zacks

    Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP

    Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP

  • Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
    Zacks

    Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review

    Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.

  • GuruFocus.com

    Pharma Company Buybacks: Do They Really Benefit Shareholders?

    Some argue cash spent on buybacks and dividends should be funneled into R&D; to develop novel therapies that create long-term value for investors Continue reading...

  • Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
    PR Newswire

    Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant

    Eli Lilly and Company (NYSE: LLY), a global healthcare and biopharmaceutical company, will invest over $470 million and create more than 460 new jobs in Durham, Governor Roy Cooper announced today. The project will bring a new state-of-the-art pharmaceutical manufacturing facility to North Carolina's Research Triangle Park.

  • Eli Lilly and Company taps Durham for 450+ jobs, new facility
    American City Business Journals

    Eli Lilly and Company taps Durham for 450+ jobs, new facility

    Eli Lilly and Company plans to bring more than 462 jobs to a new Durham County facility. The drug giant picked Durham County for a $474 million investment over competing sites in both Indiana and Pennsylvania. The announcement was made Tuesday.

  • Reuters

    Drugmakers slash prices to be eligible for China's bulk-buy program

    Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest bidding round under China's national bulk-buy program, government officials said late on Friday. Beijing has been pushing forward the program where drugmakers have to go through a bidding process and cut prices low enough to be considered over generic copies and be allowed to sell their products at public hospitals via large-volume government procurement. Some global firms such as AstraZeneca and Merck have already cautioned about intensifying price pressures on their mature brands in the world's second largest drug market, as China expands the usage of the program.

  • Benzinga

    9 Takeaways From The JPMorgan Healthcare Conference

    The JPMorgan Healthcare Conference, which showcases innovations in the industry and provides a platform to exchange ideas and insights as well as to make breaking announcements, went by without much fanfare ...

  • Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates
    Zacks

    Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

    Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

  • Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
    Zacks

    Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

    Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

  • Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO
    Reuters

    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO

    Eli Lilly and Co aims to announce roughly one $1 billion (765 million pounds) to $5 billion (3.8 billion pounds) deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week. Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

  • Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO
    Reuters

    Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO

    Eli Lilly and Co aims to announce roughly one $1 billion to $5 billion deal every quarter in 2020, its chief financial officer told Reuters, as the U.S. drugmaker looks to build up its pipeline of future products. It will focus largely on earlier stage opportunities across key therapeutic areas including oncology, pain, immunology, and neurology, CFO John Smiley told Reuters in an interview at the JP Morgan Healthcare conference in San Francisco earlier this week. Eli Lilly has been on a deal-making spree in recent years in a bid to increase products and sales in core franchises as older blockbuster medicines, such as diabetes treatment Humalog, face generic competition and pressure to lower prices.

  • Eli Lilly (LLY) Gains But Lags Market: What You Should Know
    Zacks

    Eli Lilly (LLY) Gains But Lags Market: What You Should Know

    Eli Lilly (LLY) closed the most recent trading day at $141.43, moving +0.23% from the previous trading session.

  • Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement
    PR Newswire

    Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement

    Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2019 financial results on Thursday, January 30, 2020. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.

  • FDA Risks Sacrificing Its Standards for Speed
    Bloomberg

    FDA Risks Sacrificing Its Standards for Speed

    (Bloomberg Opinion) -- Today’s Food and Drug Administration moves much faster than it used to. That may not always be a good thing. A review of drug approvals by the agency from researchers at Harvard Medical School released Tuesday found that the FDA is approving drugs more rapidly with weaker evidence than it did in the past. That can be beneficial when it leads to needed medicines getting to market quickly, and I believe that’s the agency’s intent. As the study’s authors highlight, however, this emphasis on speed and flexibility could be eroding standards. It may be time for a gut check.The gold standard for demonstrating efficacy — and the surest way of winning drug approval — is to demonstrate success in large, well-controlled studies that result in a hard outcome. But there are faster ways to get to market. In 1992, Congress created the accelerated approval program, which can green light medicines based on “surrogate” endpoints that predict rather than confirm benefit for patients, or those that have shown a shorter-term benefit. It’s one of several initiatives that have changed how the agency works. According to the study, 80.6% of approvals between 1995 and 1997 were supported by at least two pivotal trials. That number dropped to 52.8% between 2005 and 2017. Companies that get accelerated approval have to prove their drug works with a confirmatory trial in order to gain full approval, but there’s no hard timetable no when that must be done. Thus, drugmakers often don't hurry to conduct those tests. This is problematic at best, dangerous at worst.Here’s just one case: In 2016, Sarepta Therapeutics Inc. sought approval of a medicine to treat a rare muscle-wasting disease in young boys based on weak evidence from a tiny trial. In the face of significant public pressure, the FDA approved Exondys 51 even though one of its scientists called the treatment “an elegant placebo” in a report. Sarepta is selling the drug for over $300,000 a year but has continually delayed a confirmatory trial. It’s now years away from completion, and there have been no real consequences for the delay.When companies do complete post-approval trials, it sometimes reveals a mistake. Eli Lilly & Co.’s cancer drug Lartruvo got accelerated approval in 2016. Lilly then pulled the medicine from the market last year after a larger trial found no benefit. That’s a rare outcome, but there are many expensive drugs on the market that have never moved beyond surrogate endpoints. A study of 93 accelerated cancer drug approvals between 1992 and 2017 found that only 19 had proved to help patients live longer in a followup trial. There are some good reasons for faster approvals, as former FDA Commissioner Scott Gottlieb outlined in a Twitter response this week to a critical New York Times editorial penned on Jan. 11. Scientists are better at evaluating the safety of medicines and trial design has improved, for example. And advances have made it easier to create drugs that target small populations and have dramatic effects, Gottlieb wrote.He makes good points. But the agency arguably hasn’t found the right balance between embracing advances and maintaining a high bar. It certainly has a ways to go on post-approval follow up. America is entirely unable to control the price of new medicines; the approval of marginal drugs has financial consequences. The FDA will soon face one of its most important and controversial decisions yet. Biogen Inc. is seeking approval for the first purportedly disease-modifying Alzheimer’s drug — a medicine that could be used by millions of people and cost billions — without good evidence that it works. The agency often uses unmet need as a justification for shifting standards, and there’s no bigger unmet need than Alzheimer’s. That doesn’t justify an approval based on one failed trial and another that is a questionable success at best.The agency will have to decide whether to review or approve the medicine in the next year or so. This choice is an opportunity to resist public pressure and move back toward demanding firmer proof of efficacy before drugs hit the market. To contact the author of this story: Max Nisen at mnisen@bloomberg.netTo contact the editor responsible for this story: Beth Williams at bewilliams@bloomberg.netThis column does not necessarily reflect the opinion of Bloomberg LP and its owners.Max Nisen is a Bloomberg Opinion columnist covering biotech, pharma and health care. He previously wrote about management and corporate strategy for Quartz and Business Insider.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • J&J Seeks Label Expansion for Spravato Nasal Spray in EU
    Zacks

    J&J Seeks Label Expansion for Spravato Nasal Spray in EU

    J&J (JNJ) seeks label expansion for its new nasal spray, Spravato (esketamine), for an expanded patient population in Europe.

  • Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
    Zacks

    Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

    The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

  • Nektar's Pain Drug Gets Adverse Advisory Committee Decision
    Zacks

    Nektar's Pain Drug Gets Adverse Advisory Committee Decision

    Nektar (NKTR) to stop development of chronic pain candidate, NKTR-181, following two FDA advisory committees' decision to not recommend its approval.

  • Barrons.com

    Democrats Called for Cuts to Drug Prices at the Debate. The Pharma Industry Says It’s Trying.

    Pharmaceutical executives at the J.P. Morgan Healthcare conference say the industry can fixed pricing problems on its own.

  • Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins
    Zacks

    Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

    Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.

  • Benzinga

    The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 14.) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ...

  • Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease
    PR Newswire

    Lilly, Anna Kaiser Launch '30-Day Thriver Challenge' to Increase Awareness of Daily Stress of Living with Metastatic Breast Cancer, Elevate Support for Women and Men Living with the Disease

    \- An estimated 113 people die every day in the U.S. from metastatic breast cancer (MBC).1 This devastating statistic adds to the emotional and mental weight of living with incurable cancer.